A 3 adenosine receptor (A 3 AR) activation with the specific agonist CF101 has been shown to inhibit the development of colon carcinoma growth in syngeneic and xenograft murine models. In the present study, we looked into the effect of CF101 on the molecular mechanisms involved in the inhibition of HCT-116 colon carcinoma in mice. In tumor lesions derived from CF101-treated mice, a decrease in the expression level of protein kinase A (PKA) and an increase in glycogen synthase kinase-3b (GSK-3b) was observed. This gave rise to downregulation of b-catenin and its transcriptional gene products cyclin D1 and c-Myc. Further mechanistic studies in vitro revealed that these responses were counteracted by the selective A 3 AR antagonist MRS 1523 and by the GSK-3b inhibitors lithium and SB216763, confirming that the observed effects were A 3 AR and GSK-3b mediated. CF101 downregulated PKB/Akt expression level, resulting in a decrease in the level and DNA-binding capacity of NF-jB, both in vivo and in vitro. Furthermore, the PKA and PKB/Akt inhibitors H89 and Worthmannin mimicked the effect of CF101, supporting their involvement in mediating the response to the agonist. This is the first demonstration that A 3 AR activation induces colon carcinoma growth inhibition via the modulation of the key proteins GSK-3b and NF-jB.
Introduction
The A 3 AR is a G i -protein-coupled receptor containing seven a helical spanning membrane domains. A 3 AR was found to be expressed in different tumor cell lines, including Jurkat T, pineal gland, astrocytoma, melanoma as well as colon and prostate carcinoma Merighi et al., 2001; Suh et al., 2001; Trincavelli et al., 2002a; Fishman et al., 2003; Madi et al., 2003; Ohana et al., 2003) . A 3 AR activation leads to inhibition of adenylyl cyclase activity, cAMP formation and PKA expression, resulting in the initiation of various signaling pathways which may include the MAPK and the PI3K (Poulsen and Quinn, 1998; Olah and Stiles, 2000; Trincavelli et al., 2002b) .
Our earlier studies demonstrated that melanoma cells highly express A 3 AR, and suggested that it may serve as a target for tumor growth inhibition. A 3 AR activation by the synthetic agonist 1-deoxy-1- [6-[[(3-iodophenyl) methyl]amino]-9H-purine-9-yl]-N-methyl-b-D-ribofuranuronamide (IB-MECA) inhibited the growth of melanoma both in vitro and in vivo (Fishman et al., , 2002a (Fishman et al., , b, 2003 Ohana et al., 2001; Madi et al., 2003) . The mechanistic pathway involved downregulation of the Wnt signaling pathway. It was found that IB-MECA inhibited the expression of PKAc and PKB/Akt, thereby preventing the phosphorylation and inactivation of GSK-3b. Consequently, GSK-3b was shown to phosphorylate b-catenin and prevent its translocation to the nucleus, resulting in downregulation of cyclin D1 and cMyc (Fishman et al., 2002b; Madi et al., 2003) . PKB/ Akt is also known to control NF-kB level by phosphorylating downstream proteins, which in turn release NFkB from its complex (Madrid et al., 2001) . Similar to bcatenin, NF-kB translocates to the nucleus, where, among other genes, it induces the transcription of c-Myc and cyclin D1 (Joyce et al., 2001) .
Our previous studies showed that CF101 is efficacious in suppressing the growth of primary and liver metastasis of CT-26 colon carcinoma cells in syngeneic experimental tumor models in mice (Ohana et al., 2003) . In addition, CF101 inhibited the growth of subcutaneous HCT-116 human colon carcinoma cells in a xenograft model in mice.
Aberrant activation of Wnt signaling, caused by mutations in b-catenin or APC, is a critical event in the development of colorectal tumors. In these cases, GSK-3b fails to phosphorylate b-catenin, which accumulates in the cytoplasm. b-catenin then translocates to the nucleus where, in association with Lef/Tcf, it induces the transcription of cyclin D1 and c-Myc (Morin, 1999) .
The present study is focused on the molecular mechanism involved in the inhibition of colon carcinoma growth by CF101. We explored the signaling modulation of GSK-3b and NF-kB, both of which are affected by PKB/Akt (which is downstream to PI3K) and are known to regulate the level of the important oncogenes cyclin D1 and c-Myc. A major role for GSK3b in mediating these responses is discussed. , the mice were treated daily orally with CF101. Tumor growth was suppressed in the CF101-treated group in comparison to the vehicletreated group (Figure 1a) . On the day of study termination, 52 þ 6.1% (Po0.001) tumor growth inhibition was observed. To evaluate the effect of chronic CF101 treatment on A 3 AR expression and downstream cell growth-regulatory proteins, extracts were prepared from tumor lesions and subjected to Western blot (WB) analysis. In the group of mice killed 2 h after the last treatment, the expression level of A 3 AR, PKAc, bcatenin, NF-kB, c-Myc and cyclin-D1 was downregulated, whereas GSK-3b was upregulated. In the group of mice killed 16 h after the last treatment, A 3 AR expression was similar to that of the vehicle-treated group. Interestingly, in this group, most of the cell growthregulatory proteins were decreased in comparison to the control group, indicating that continuous downregulation is achieved upon chronic CF101 treatment. Taken together, these data show that receptor downregulation occurs shortly (2 h) after CF101 treatment, leading to modulation of downstream proteins, and that A 3 AR was not desensitized despite chronic activation (over a 20-day period). The expression of the receptor returned to normal levels 16 h after CF101 administration, demonstrating that, even after chronic activation, the receptor is fully expressed (Figure 1b ).
Results

CF101 inhibits colon carcinoma growth
CF101 modulates the expression level of A 3 AR and downstream cell growth-regulatory proteins in vitro
To further study the association between A 3 AR activation and the expression of downstream cell growthregulatory proteins, HCT-116 colon carcinoma cells were incubated in the presence of CF101 (10 nM) for 15 min. Proteins were extracted and analysed by WB. Similar effects of CF101 to those seen in vivo were recorded. The expression level of the two kinases PKAc and PKB/Akt was downregulated, while the expression of their downstream substrate GSK-3b was upregulated. The levels of the coactivator b-catenin and the downstream target genes cyclin D1 and c-Myc were decreased (Figure 2a) . To confirm that these responses are mediated via the A 3 AR, the antagonist MRS 1523 was introduced to the culture system. The antagonist counteracted the effect of CF101, thereby retaining the control levels of PKAc, GSK-3b and cyclin D1, demonstrating the specificity of the response (Figure 2b ). To further elucidate the role of PKA and , and was given twice daily for 21 consecutive days. On day 21, the mice were killed 2 or 16 h after CF101 treatment. Tumor lesions were removed and protein extracts were prepared. (a) Tumor size was measured every 4 days. The curve represents a comparison between the vehicle and CF101-treated groups. (b) Immunoblots showing the effect of CF101 on cell growth-regulatory proteins derived from the colon carcinoma tumor lesions. A 3 AR was downregulated 2 h after treatment and fully expressed after 16 h. Downstream cell growth-regulatory proteins were modulated upon CF101 treatment A 3 adenosine receptor agonist suppresses colon carcinoma P Fishman et al PKB in mediating cell response to CF101, their activity was mimicked by H89 and Worthmannin (PKA and PKB/Akt inhibitors, respectively). Figure 2c depicts an increase in GSK-3b level upon treatment with the two inhibitors.
CF101 deregulates GSK-3b and downstream key signaling proteins
The next set of experiments was carried out to assure that CF101 decreased cyclin D1 and c-Myc levels via modulation of GSK-3b. We therefore compared the active nonphosphorylated GSK-3b level to its nonactive phosphorylated form. Consistent with the former data, we found that, upon CF101 treatment, the nonphosphorylated form was upregulated, whereas the phosphorylated one was decreased ( Figure 3a) . SB216763, an inhibitor to GSK-3b, counteracted the ability of CF101 to downregulate c-Myc, confirming that this response was GSK-3b mediated ( Figure 3b ). Furthermore, marked increase in the activity of GSK-3b was also noted after 15 and 30 min ( Figure 3c ). To assess whether the decrease in b-catenin is mediated via its phosphorylation by GSK-3b, HCT-116 cells were treated with lithium chloride that inhibits the serine/threonine phosphorylation activity of GSK-3b. Indeed, lithium treatment reversed the decrease in b-catenin expression level (36 þ 3.4%, Po0.002), confirming that this response is GSK-3b mediated ( Figure 3d ). In addition, the nuclear level of LEF-1 in the CF101-treated cells was downregulated (Figure 3e ), supporting the notion that less b-catenin was associated with LEF-1 and subsequently translocated to the nucleus.
Effect of CF101 on the level and transcription activity of NF-kB
Activated PKB/Akt can phosphorylate IkB kinase, leading to further phosphorylation events and the release of NF-kB from its complex with IkB. Accordingly, we examined whether the downregulation of PKB/Akt will affect the protein expression and DNAbinding capacity of NF-kB, also known to induce cyclin D1 and c-Myc transcription. Indeed, decreased NF-kB level was seen in protein extracts derived from CF101-treated HCT-116 cells ( Figure 4a ). This decrease was blocked when the antagonist MRS 1523 was present in the culture medium together with CF101, demonstrating the specificity of this response. Moreover, electrophoretic mobility shift assay (EMSA) conducted with cell nuclei extracts revealed marked reduction in NF-kB DNA-binding capacity at 15, 30 and 60 min, suggesting a reduction in the NF-kB transcription activity at these time points (Figure 4b ).
Discussion
In the present study, we followed the downstream signaling events taking place subsequent to A 3 AR activation, resulting in tumor growth inhibition. These studies were conducted in a xenograft nude mice model, and were confirmed in vitro.
In mice treated chronically for 20 days with CF101, receptor protein downregulation was noted shortly after CF101 administration. Later on, prominent A 3 AR expression was noted, demonstrating that A 3 AR was fully expressed in the tumor cells after chronic treatment with CF101. These fluctuations may be attributed to receptor internalization, degradation and re-synthesis, which occurs subsequent to receptor activation. These data are the first to show A 3 AR expression in vivo, and support the notion that colon carcinoma cells do not develop 'resistance' or 'tolerance' to chronic treatment with a synthetic A 3 AR agonist. Supporting the above is our recent publication demonstrating that, upon activation of B16-F10 melanoma cells with IB-MECA, A 3 AR was internalized and sorted to the lysosome for degradation. Later on, the receptor was resynthesized and recycled to the cell surface .
In the present study, receptor functionality was demonstrated by the modulation in the expression level of key signaling cell growth-regulatory proteins downstream to receptor activation. This included downregulation of PKAc and PKB/Akt and upregulation of GSK-3b. Additionally, the protein expression levels of b-catenin, LEF-1 and the two oncogenes cyclin D1 and c-Myc were found to be decreased.
These results are in accordance with our previous studies, which showed decreased PKAc and PKB/Akt levels upon treatment of B16-F10 melanoma cells with IB-MECA (Fishman et al., 2002b; Madi et al., 2003) . PKAc is the catalytic subunit of PKA, known to be activated subsequent to increase in cAMP level. Activation of A 3 AR is known to decrease adenylyl cyclase activity and cAMP formation, resulting in a decline in PKAc level. PKB/Akt has recently been shown to be phosphorylated and thereby activated by PKAc (Fang et al., 2000) . The PI3K arm was reported to be upregulated upon A 3 AR activation via the bg-subunit (Schutle and Fredholm, 2002) , leading to an increase in the phosphorylated form of PKB/Akt. Here, we show that, in colon carcinoma cells, downregulation of PKB/ Akt takes place upon receptor activation, suggesting that in tumor cells modulation of the PKA arm is the dominant event, leading to the downregulation of PKB/ Akt. PKAc and PKB/Akt utilize GSK-3b as a substrate and, upon phosphorylation, GSK-3b activity is inhibited. The latter has been widely implicated in cell homeostasis, by its ability to phosphorylate a broad range of substrates including b-catenin, a key component of the Wnt pathway (Ferkey and Kimelman, 2000) . In normal cells, GSK-3b phosphorylates b-catenin, thereby inducing its ubiquitination and degradation by the proteosome system (Morin, 1999) . However, in tumor cells, GSK-3b fails to phosphorylate b-catenin, leading to its accumulation in the cytoplasm. It then translocates to the nucleus, where it acts in concert with LEF-1 to induce the transcription of the cell cycle progression genes such as cyclin D1 and c-Myc (Kolligs et al., 2002) .
In previous studies, we showed that A 3 AR activation induced downregulation of cyclin D1 and c-Myc in melanoma and prostate carcinoma cells, via deregulation of some Wnt signaling proteins (Fishman et al., 2002b Madi et al., 2003) . We thus assume that the decreased expression level of b-catenin is responsible for the diminished level of cyclin D1 and c-Myc.
In the present study, we examined the effect of CF101 on HCT-116 colon carcinoma cells, known to be mutated in the b-catenin gene (CTNNB1) (Lovig et al., 2002) . Mutations of CTNNB1 were found at the GSK3b consensus phosphorylation site of b-catenin, that is, a deletion of serine 45 that occurs at a putative phosphorylation target of GSK-3b (Ilyas et al., 1997) . Surprisingly, we found that downregulation of b-catenin expression, which occurred upon CF101 treatment, was subsequent to an increase in the level of GSK-3b, notwithstanding the previously described, aforementioned mutation. Moreover, treatment of the cells with lithium, which directly inhibits the activity of GSK-3b, reversed the b-catenin level to that of the control. It thus seems that CF101 circumvents the inability of GSK-3b to phosphorylate b-catenin, leading to its susceptibility to degradation. Support for the involvement of bcatenin in the downregulation of cyclin D1 and c-Myc may be found in the data showing that nuclear level of LEF-1 was downregulated upon CF101 treatment. Furthermore, the GSK-3b inhibitor SB216763 counteracted the ability of CF101 to downregulate c-Myc, thus confirming that the events downstream to b-catenin are also mediated via GSK-3b.
An additional mechanism which may account for the downregulation of c-Myc and cyclin D1 is the direct phosphorylation of the two oncogenes by GSK-3b. It was recently shown that GSK-3b phosphorylates c-Myc at Thr-58 and cyclin D1 at Thr-286, thereby triggering their degradation (Alt et al., 2000; Sears et al., 2000) .
The decreased level of PKB/Akt prompted us to examine the involvement of an additional important signaling protein, NF-kB, known to be phosphorylated and activated by PKB/Akt and additional downstream kinases. Since NF-kB is also involved in the transcription of cyclin D1 and c-Myc (Karin et al., 2002) , its decreased level may also attribute to the diminished expression of the two cell cycle genes.
The Wnt and the NF-kB signaling pathways are interconnected at the level of cyclin D1 and c-Myc. Both b-catenin and NF-kB control the transcription of these genes, thereby acting as a sensor for growth signals. Taken together, we propose here a model in which activation of the A 3 AR induces modulation of PKAc and PKB, which on one hand upregulates GSK-3b, leading to phosphorylation and ubiquitination of bcatenin. On the other hand, remarkably, the similarity between the in vitro and in vivo data supports the notion that signaling proteins involved with the Wnt and NFkB pathways are responsible for the observed modulation of cell growth-regulatory proteins.
The finding that cyclin D1 and c-Myc were downregulated upon A 3 AR activation both in vitro and in vivo is highly important in light of the bulk literature showing that most human cancers are characterized by overexpression of the two oncogenes (Hosokawa and Arnold, 1998; Parrella, 2001; Masuda et al., 2002) . In some malignancies, overexpression of these proteins may serve as a marker of poor prognosis (Chana et al., 2002; Nguyen et al., 2003) . The importance of these two oncogenes in modulating the tumorigenic response was evidenced by the introduction of an antisense cyclin D1 or c-Myc sequence to malignant cells. This led to the inhibition of growth, the induction of apoptosis and the enhancement of sensitivity to chemotherapeutic agents (Van Waardenburg et al., 1997) . Additionally, Jain et al. Taken together, the molecular model that transpires upon activation of A 3 AR with CF101 includes downregulation of PKAc with a subsequent decrease in PKB/ Akt expression level. This may lead on one hand to upregulation of the unphosphorylated form of GSK-3b and the phosphorylation and ubiquitination of bcatenin, resulting in the inhibition of translation of cyclin D1 and c-Myc. Additional events taking place downstream to PKB/Akt include decreased expression and DNA-binding capability of NF-kB, leading also to downregulation of cyclin D1 expression level.
The capability of CF101, a small orally bioavailable molecule, to downregulate cyclin D1 and c-Myc levels both in vitro and in vivo suggest that the compound is an attractive candidate to be developed as an anticancer agent.
Materials and methods
Reagents
CF101 is a GMP grade of the A 3 AR agonist 1-deoxy-1-amino]-9H-purine-9-yl]-N-methyl-(-D-ribofuranuronamide) (IB-MECA), and was synthesized for Can-Fite BioPharma by Albany Molecular Research Inc., Albany, NY, USA. MRS 1523, a highly selective A 3 AR antagonist, was purchased from RBI/Sigma (Natick, MA, USA). For both reagents, a stock solution of 10 mM was prepared in DMSO and further dilutions in RPMI medium were performed. Lithium chloride and H89 were purchased from Sigma Israel, and SB216763 was purchased from Biomol Research Laboratories Inc. (Plymouth, USA). RPMI, fetal bovine serum (FBS) and antibiotics for cell cultures were obtained from Beit Haemek, Haifa, Israel.
Rabbit polyclonal antibodies against murine and human A3AR and the cell growth-regulatory proteins PKAc, PKB/ Akt, c-Myc, GSK-3b, phosphor-specific GSK-3b (S9), bcatenin, cyclin D1 and LEF-1 and b-actin were purchased from Santa Cruz Biotechnology Inc., CA, USA.
Effect of CF101 on the growth of HCT-116 colon carcinoma in nude mice and assessment of A 3 AR expression and cell growthregulatory proteins in tumor lesions
Mice were maintained on a standardized pelleted diet and supplied with tap water. Experiments were performed in accordance with the guidelines established by the Institutional Animal Care and Use Committee at Can-Fite BioPharma, Petah Tikva, Israel.
Nude male Balb/c mice, aged 2 months, weighing an average of 20 g, were obtained from Harlan Laboratories, Jerusalem, Israel. HCT-116 colon carcinoma cells (1.2 Â 10 6 ) were subcutaneously injected into the flank of the mice. When tumor reached 150 mm 3 in size, CF101 (10 mg/kg body weight) was administered orally twice daily for 20 days. The control group was treated orally twice daily with the vehicle only. Tumor size (width (W) and length (L)) was measured twice weekly with a caliber, and calculated according to the following formula: tumor size ¼ (W) 2 Â L/2. After 20 days of treatment and prior to terminating the study, the CF101-treated mice were divided into two groups. (A) mice treated for 20 days with CF101 and killed 16 h after last treatment; (B) mice treated for 20 days with CF101, received additional treatment on day 21 and killed 2 h later. Tumor lesions from the two groups and the control were then excised, homogenized (Polytron, Kinematica) and protein was extracted. WB analysis was carried out to determine the A 3 AR expression level and additional cell growth-regulatory proteins. Each group contained 15 mice and the study was repeated three times. The results depicted are a representative experiment.
WB analysis
WB analysis of the following samples was carried out: (A) tumor lesions derived from CF101 and vehicle-treated nude mice inoculated with HCT-116 colon carcinoma cells (detailed above). (B) HCT-116 human colon carcinoma cells were serum starved overnight and then incubated with CF101 (10 nM or 10 mM) in the presence and absence of MRS 1523 (100 nM), H89 (10 mM), Worthmanin (100 nM), and/or SB216763 (1 mM) for time periods, as specified below, at 371C. Samples were rinsed with ice-cold PBS and transferred to ice-cold lysis buffer (TNN buffer, 50 mM Tris buffer pH ¼ 7.5, 150 mM NaCl, 0.5% NP-40). Cell debris were removed by centrifugation for 10 min, at 7500 g. Protein concentrations were determined using the Bio-Rad protein assay dye reagent. Equal amounts of the sample (50 mg) were separated by SDS-PAGE, using 12% polyacrylamide gels. The resolved proteins were then electroblotted onto nitrocellulose membranes (Schleicher & Schuell, Keene, NH, USA). Membranes were blocked with 1% BSA and incubated with the desired primary antibody (dilution 1:1000) for 24 h at 41C. Blots were then washed and incubated with a secondary antibody for 1 h at room temperature. Bands were recorded using BCIP/NBT color development kit (Promega, Madison, WI, USA). Data presented in the different figures are representative of at least four different experiments.
Preparation of nuclear extracts
Nuclear extract proteins from CF101-treated and control HCT-116 cells were prepared by incubating the cells for 15 min on ice in a buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 1 mM DTT and 0.5 mM PMSF. Following incubation, Nonident P-40 (10%) was added, cells were vortexed for 10 s and centrifuged. The pellet was resuspended in a buffer containing 20 mM HEPES (pH ¼ 7.9), 400 mM NaCl, 1 mM EDTA, 1 mM DTT and 1 mM PMSF, rocked on a shaker for 15 min at 41C and centrifuged. Protein was quantified utilizing Bio-Rad protein assay dye reagent.
GSK-3b immunoprecipitation
HCT-116 human colon carcinoma cells were serum starved overnight and then incubated with CF101 (10 mM) for 30 min at 371C. After isolating protein, 300 mg from each sample was removed for immunoprecipitation. The samples were cleared by incubating for 2 h with 1 mg/sample of rabbit IgG and 10 ml/ sample of GammaBind Sepharose (Pharmacia, Piscataway, NJ, USA). After centrifuging, the supernatants were transferred to a tube containing 3 mg/sample of Ab against GSK-3b bound to GammaBind Sepharose, and then rotated at 41C overnight. The beads were subsequently washed three times with high salt buffer (1 M Tris-HCl pH 7.4, 0.50 M NaCl, and 1% Nonidet P-40) and three times with lysis buffer without protease inhibitors. The immunoprecipitated complexes were used in a kinase activity assay.
GSK-3b activity assay
After immunoprecipitating GSK-3b from HCT-116 cells, the protein-containing pellet was washed twice with kinase buffer (20 mM MgCl 2 , 25mM HEPES, 20 mM glycerophosphate, 20 mM p-nitrophenylphosphate, 20 mM sodium orthovanadate and 2 mM DTT). The pellet was then suspended in 20 ml kinase buffer and the following ingredients were added: 20 mM ATP, 5 mCi ATP (BLU 002Z; DuPont-NEN, Boston, MA, USA) and 10 mg myelin basic protein (MBP; Sigma). The total volume of sample plus additions at this point was 25 ml. The reaction was continued for 30 min at 251C and then stopped by the addition of 25 ml/sample of 2 Â sample buffer. The samples were boiled for 5 min, then run on a 12% SDS-PAGE gel. The gel was dried, and autoradiography performed to visualize the 32 P-labeled MBP.
EMSA of NF-kB
To carry out the gel shift assay, double-stranded oligonucleotides for the consensus sequence of NF-kB (5 0 -AGTT-GAGGGGACTTTCCCAGGC-3 0 ) were end-labeled with 32 ATP (Amersham) using polynucleotide kinase (Promega). Nuclear protein extracts (3 mg) were incubated for 30 min at room temperature with the end-labeled DNA (1 mg) in binding buffer containing 5 mM MgCl 2 , 250 mM NaCl, 2.5 mM DTT, 25 mM EDTA, 20% glycerol, 50 mM Tris-HCl pH 7.5 and 2 mg/sample of poly (dI-dC), in a final volume of 25 ml. Competition with unlabeled oligonucleotide of NF-kB binding sequence at a 100-fold molar excess was used to analyse specific bands. The reaction product was analysed by 6% nondenaturating polyacrylamide gel electrophoresis. The specific bands were visualized by X-ray autoradiography.
Statistical analysis
The results were evaluated using the Student's t-test, with statistical significance set at Po0.05. Comparison between the mean values of different experiments was carried out.
